NASDAQ:THRX Theseus Pharmaceuticals (THRX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.06▼$4.0650-Day Range$4.06▼$4.0752-Week Range$2.05▼$12.37VolumeN/AAverage Volume592,167 shsMarket Capitalization$179.57 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get Theseus Pharmaceuticals alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Theseus Pharmaceuticals Stock (NASDAQ:THRX)Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.Read More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here THRX Stock News HeadlinesMay 20, 2024 | bbc.co.ukKS2 / KS3 English: A Midsummer Night's Dream. 1: Welcome to AthensFebruary 14, 2024 | finance.yahoo.comTheseus Pharmaceuticals Announces Closing of Tender OfferJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.February 14, 2024 | prnewswire.comTheseus Pharmaceuticals Announces Closing of Tender OfferJanuary 30, 2024 | finance.yahoo.comConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsJanuary 20, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, THRX, GRCL, ROVRDecember 31, 2023 | businesswire.comTHESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...December 29, 2023 | finance.yahoo.comIs Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.December 27, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONNDecember 22, 2023 | marketwatch.comTheseus Pharmaceuticals Shares Rise 9.3% on Deal to Be Acquired by ConcentraDecember 22, 2023 | marketwatch.comConcentra Biosciences to Acquire Theseus Pharmaceuticals for $3.90 to $4.05/ShrDecember 22, 2023 | markets.businessinsider.comTheseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In CashDecember 22, 2023 | tmcnet.comTHRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to ShareholdersDecember 22, 2023 | finance.yahoo.comTheseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightNovember 27, 2023 | msn.comUP Fintech, Cerence, Irsa Inversiones Y Representaciones among premarket gainers packNovember 27, 2023 | markets.businessinsider.comTheseus Pharma To Evaluate Expression Of Interest From Foresite, OrbiM And Proposal From ConcentraNovember 27, 2023 | finance.yahoo.comTheseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCSee More Headlines Receive THRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:THRX CUSIPN/A CIK1745020 Webtheseusrx.com Phone857-400-9491FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+72.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.84% Return on Assets-23.64% Debt Debt-to-Equity RatioN/A Current Ratio29.93 Quick Ratio29.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.36 per share Price / Book0.76Miscellaneous Outstanding Shares44,230,000Free Float23,575,000Market Cap$179.57 million OptionableOptionable Beta3.98 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Iain D. Dukes DPHIL (Age 66)M.A., Co-Founder & Chairman Comp: $67.28kMr. Bradford D. Dahms (Age 36)President, CFO & Director Comp: $480.95kMs. Kristine Callahan CPAVP & ControllerKey CompetitorsVeruNASDAQ:VERUKinnate BiopharmaNASDAQ:KNTEMarinus PharmaceuticalsNASDAQ:MRNSOyster Point PharmaNASDAQ:OYSTLianBioNASDAQ:LIANView All Competitors THRX Stock Analysis - Frequently Asked Questions How were Theseus Pharmaceuticals' earnings last quarter? Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) issued its quarterly earnings results on Monday, November, 15th. The company reported ($5.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $4.93. When did Theseus Pharmaceuticals IPO? Theseus Pharmaceuticals (THRX) raised $150 million in an initial public offering on Thursday, October 7th 2021. The company issued 10,000,200 shares at $14.00-$16.00 per share. This page (NASDAQ:THRX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theseus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theseus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
